Zynerba Pharmaceuticals Stock News

DEVON, Pa., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba, will virtually present a company overview during the 11 th Annual SVB Leerink Global Healthcare Conference on Friday, February 18, 2022 at 8:40 a.m. ET.

WASHINGTON, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Vantage Market Research''s recent analysis of the Global Cannabidiol (CBD) Market finds that increasing awareness of cannabidiol''s therapeutic benefits is expediting market growth. Primarily driven by increasing demand for cannabidiol (CBD) for health and wellness purposes is high, the total Global Cannabidiol (CBD) Market is estimated to reach USD 47.22 Billion by 2028, up from USD 4.9 Billion in 2021, at a compound annual growth rate (CAGR) of 21.3%. Furthermore, rising acceptance and use of CBD products due to government approvals to augment the growth of the Global Cannabidiol (CBD) Market, states Vantage Market Research, in a report, titled " Cannabidiol (CBD) Market by Source (Hemp, Marijuana), by Distribution Channel (Online, Offline), by End-Use (Medical, Personal Use, Pharmaceuticals, Wellness), by Region (North America, Latin America, Europe, Asia Pacific) - Global Industry Assessment (2016 - 2021) & Forecast (2022 - 2028)". Click Here To Access The Free Sample Report @ https://www.vantagemarketresearch.com/cannabidiol-cbd-market-1252/request-sample (The Free Sample Of This Report Is Readily Available On Request).

Zynerba Pharmaceuticals Inc (ZYNE) shares closed 1.2% lower than its previous 52 week low, giving the company a market cap of $108M. The stock is currently down 8.7% year-to-date, down 23.8% over the past 12 months, and down 86.4% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 rose 0.6%. Trading Activity Trading volume this week was 90.6% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.6. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 1504.9% The company's stock price performance over the past 12 months lags the peer average by 48.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Zynerba Pharmaceuticals Inc (ZYNE) shares closed today at 1.9% above its 52 week low of $2.58, giving the company a market cap of $112M. The stock is currently down 5.6% year-to-date, down 21.2% over the past 12 months, and down 85.8% over the past five years. This week, the Dow Jones Industrial Average fell 1.4%, and the S&P 500 fell 1.6%. Trading Activity Trading volume this week was 47.9% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.6. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -677.8% The company's stock price performance over the past 12 months lags the peer average by 40.0% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

The Best Daily Overview Of The Cannabis Space CV Sciences Announces New Distribution Agreement with GNC. $CVSI Massachusetts cannabis prices continue to fall Kentucky GOP Sen. Damon Thayer: "M

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Annexon Announces Mixed Phase 2 Data From Huntington Disease Trial Annexon, Inc. (NASDAQ: ANNX) announ

Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) has decided not to advance Zygel against developmental and epileptic encephalopathies (DEE). The decision was in line with the feedback from the FDA, whic

– Company plans to focus development of Zygel™ in FXS, ASD and 22q –

Zynerba Pharmaceuticals Inc has provided program updates for Fragile X syndrome (FXS), autism spectrum disorder (ASD), 22q11.2 deletion syndrome (22q), and developmental and epileptic encephalopathie

Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE)s traded shares stood at 0.45 million during the last session, with the companys beta value hitting 2.29. At the close of trading, the stocks price was $3.32, to imply a decrease of -3.77% or -$0.13 in intraday trading. The ZYNE shares 52-week high remains $9.00, putting it -171.08% down since that Boom Or Bust: What Are Zynerba Pharmaceuticals Inc.s (NASDAQ:ZYNE) Future Prospects? Read More »

Equities analysts predict that Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) will report earnings of ($0.26) per share for the current quarter, according to Zacks. Zero analysts have issued estimates for Zynerba Pharmaceuticals earnings, with the highest EPS estimate coming in at ($0.24) and the lowest estimate coming in at ($0.28). Zynerba Pharmaceuticals reported earnings per share of []

DEVON, Pa., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rar

DEVON, Pa., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced presentation details for The BRAIN Foundation Synchrony 2021 Symposium, being held virtually December 11-12, 2021. The presentation can be accessed by registering for free at https://synchronysymposium.com/ . A copy of the presentation slides will be made available on the Zynerba corporate website following the presentation at http://zynerba.com/publications/ .

Charles Schwab Investment Management Inc. acquired a new stake in Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) during the second quarter, Holdings Channel reports. The institutional investor acquired 18,093 shares of the companys stock, valued at approximately $96,000. Several other institutional investors and hedge funds also recently modified their holdings of the company. Goldman Sachs Group Inc. boosted []

Zynerba Pharmaceuticals, Inc. (ZYNE) with the stream of -2.22% also noticed, India Regis Corporation (RGS) encountered a rapid change of -3.46% in the last hour of Mondays trading session. Zynerba The post Glistering Stock: Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), Regis Corporation (NYSE:RGS) appeared first on Stocks Equity .